Relevant bibliographies by topics / Diabetes – Prevention

Academic literature on the topic 'Diabetes – Prevention'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Diabetes – Prevention.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Diabetes – Prevention"

1

Barclay, Chris, and Nigel Mathers. "Diabetes prevention." British Journal of General Practice 58, no. 557 (December 1, 2008): 887.2–887. http://dx.doi.org/10.3399/bjgp08x376249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Davis-Lameloise, Nathalie, Benjamin Philpot, Prasuna Reddy, and James A. Dunbar. "Diabetes prevention." British Journal of General Practice 58, no. 557 (December 1, 2008): 887.3–888. http://dx.doi.org/10.3399/bjgp08x376258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kelly, Sarah Dion. "Diabetes Prevention." Physician Assistant Clinics 7, no. 1 (January 2022): 1–12. http://dx.doi.org/10.1016/j.cpha.2021.08.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Piper, Sarah. "Diabetes Prevention." AADE in Practice 1, no. 1 (January 2013): 10–13. http://dx.doi.org/10.1177/2325160312471799.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moses, Alan C., Michael Mawby, and Anne M. Phillips. "Diabetes Prevention." American Journal of Preventive Medicine 44, no. 4 (April 2013): S333—S338. http://dx.doi.org/10.1016/j.amepre.2012.12.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brooks, John L. "Diabetes Prevention." American Journal of Preventive Medicine 44, no. 4 (April 2013): S299—S300. http://dx.doi.org/10.1016/j.amepre.2013.01.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sodikovna, Abdurazakova Dilbar, Yusupova Shahnoza Kadirjanovna, SaidjonovaFeruza Latifjonovna, and Jabbarov Ibrohimjon Adhamjon O’gli. "PREVENTION OF TYPE 2 DIABETES MELLITUS." American Journal Of Biomedical Science & Pharmaceutical Innovation 4, no. 3 (March 1, 2024): 44–51. http://dx.doi.org/10.37547/ajbspi/volume04issue03-06.

Full text
Abstract:
Prevention of type 2 diabetes mellitus and complications is an urgent problem in modern medicine. In patients with a body mass index (BMI) above 25 kg/m2, indicators of markers of carbohydrate metabolism (serum glucose -fasting and postprandial glycemia, glycosylated hemoglobin and urine glucose) and lipid metabolism -total cholesterol (TC), triglycerides (TG), lipidogram (low-density lipoprotein cholesterol -LDL cholesterol, atherogenic index -AI is significantly higher, and high-density lipoprotein cholesterol -HDL cholesterol is significantly lower than in patients with normal body mass index (BMI) and abdominal index (AI). Asignificant positive relationship between age, abdominal index, BMI, AI, glucose level in blood serum. Assessment of markers of carbohydrate and lipid metabolism should be included in the list of mandatory examinations of patients over the age of 30 years, and be strictly individual. There is a relationship between the progression of carbohydrate metabolism disorders and changes in lipid parameters metabolism in the examined women.The population should be widely informed about the development of type 2 diabetes mellitus and the progression of complications.
APA, Harvard, Vancouver, ISO, and other styles
8

Aroda, Vanita R., William C. Knowler, Jill P. Crandall, Leigh Perreault, Sharon L. Edelstein, Susan L. Jeffries, Mark E. Molitch, et al. "Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study." Diabetologia 60, no. 9 (August 2, 2017): 1601–11. http://dx.doi.org/10.1007/s00125-017-4361-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Azizur Rahman, Mohammad, and Rabeya Akter. "Diabetes Ameliorating Effect of Mushrooms and ameliorating diabetes." Diabetes and Islet Biology 5, no. 1 (January 11, 2022): 01–05. http://dx.doi.org/10.31579/2641-8975/026.

Full text
Abstract:
The growing impact of type 2 diabetes in the majority of the population requires the introduction of better and more secure treatments, but also requires the development of new prevention strategies to reduce the incidence and prevalence of the disease. Significantly, type 2 diabetes is an important preventable disease and can be prevented or delayed by lifestyle intervention. Edible and medicinal macrofungi, mushrooms have been reported having diabetes ameliorating effects. Current study reviews the potentiality of both edible and medicinal mushrooms in preventing and ameliorating the diabetic complications as well as the future aspects of mushrooms against this metabolic disorder.
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Diabetes Prevention Trial." Endocrinologist 6, no. 5 (September 1996): 417. http://dx.doi.org/10.1097/00019616-199609000-00011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Diabetes – Prevention"

1

Beales, Philip Edward. "Diabetes prevention in the non-obese diabetic mouse." Thesis, University of East London, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Neumann, Anne. "Prevention of type 2 diabetes : modeling the cost-effectiveness of diabetes prevention." Doctoral thesis, Umeå universitet, Epidemiologi och global hälsa, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-123553.

Full text
Abstract:
Background: Diabetes is a common and costly disease that is expected to continue even to grow in prevalence and health expenditures over the coming decades. Type 2 diabetes is the most common diabetes type and is characterized by insulin resistance and relative insulin deficiency. Type 2 diabetes develops over a long period and is often undetected over years. During this time, people almost always first develop any of the pre-diabetic states, i.e. impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or a combination of both (IFG&IGT). This thesis focuses on type 2 diabetes only. In the following, the term diabetes is used to refer to type 2 diabetes only. Diabetes is associated with a sedentary lifestyle and obesity. While those are not the only factors contributing to the development and maintenance of diabetes, several studies have shown that prevention of diabetes among individuals at high risk through lifestyle change is possible, effective and cost-effective, especially targeting diet and exercise to reduce weight. No previous study had, however, estimated the cost-effectiveness of diabetes prevention strategies from a population-based perspective including healthy individuals and also considered IFG and IGT as two distinct pre-diabetic states. Objective: The overall objective of this thesis was to establish, describe and evaluate a model that can assess the cost-effectiveness of lifestyle intervention programs to prevent diabetes. Methods: First, a Markov Model was established using data from the literature. The cost of a German diabetes prevention program was estimated. Second, risk equations for change to worsened glucose states were estimated using factor analysis and logistic regression based on consecutive data from the Västerbotten Intervention Program (VIP). The risk equations described transition probabilities in the final model and were based on several risk factors such as age, sex, physical activity and smoking status. Third, information on the Short-Form 36 questionnaire from the VIP population was transformed into Short-Form 6D. Health utility weights (HUW) by glucose group and four risk factors were estimated using beta regression. Fourth, an updated Markov model was established using an updated model structure compared to the one in Paper I, program costs of Paper I, risk equations of Paper II, health utility weights of Paper III and updated cost and mortality estimates. Results: The first model in Paper I showed that lifestyle intervention programs have the potential to be cost-effective with a high degree of uncertainty. The risk equations in Paper II indicated that the impact of each risk factor depended on the starting and ending pre-diabetes state, where high levels of triglyceride, hypertension, and high body mass index were the strongest risk factors to transit to a worsened glucose state. The overall mean HUW in Paper III was 0.764 with healthy individuals having the highest HUW, those with diabetes the lowest and those in pre-diabetic states ranging in between. The intervention described in Paper IV was cost-effective for all sex and age scenarios ranging from 3,833 EUR/QALY gained (women, 30 years) to 9,215 EUR/QALY gained (men, 70 years). The probability that the intervention is cost-effective was high (85.0-91.1%). Conclusion: We established a model that can estimate the cost-effectiveness of different scenarios of initiatives to prevent diabetes. The prevention or the delay of the onset of diabetes is feasible and cost-effective. A small investment in a healthy lifestyle with the change in physical activity and diet together with weight loss can have a decent, cost-effective result. The full range of possibilities this model offers has not been evaluated so far. We have, however, shown that implementing a lifestyle intervention program like the Västerbotten Intervention Programme would be cost-effective.
APA, Harvard, Vancouver, ISO, and other styles
3

Swan, Wendy Elizabeth. "Diabetes prevention in women with previous gestational diabetes /." Connect to thesis, 2008. http://repository.unimelb.edu.au/10187/5742.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schetzina, Karen E. "School-Based Type II Diabetes Prevention." Digital Commons @ East Tennessee State University, 2008. https://dc.etsu.edu/etsu-works/5026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McCracken, Jane E. "Pathogenesis and prevention of diabetes-induced embryopathy." Thesis, University of Edinburgh, 1999. http://hdl.handle.net/1842/21403.

Full text
Abstract:
Established IDDM in the BB/E rat was associated with severe disturbance in the development of the pre-implantation embryo, as indicated by (1) a five fold increase in the number of unfertilised oocytes, (2) a reduced percentage of expanded blastocytes, and (3) a -20% inner cell mass (ICM) cellular deficit in embryos which reached the expanded blastocyst stage. Data obtained from pregnant Diabetes Prone (DP) BB/E rats during the pre-diabetic period (when the maternal metabolic profile was normal), showed that the full complement of IDDM susceptibility genes was not in itself, sufficient to disturb early embryo development and/or give rise to an ICM cell deficit. In addition, experiments involving the transfer of two-cell embryos showed that the oviductal/uterine environment of a Diabetic DP-BB/E recipient could induce not only an ICM deficit but also a TE cell accretion in embryos from Non-Diabetic Diabetes Resistant (DR) BB/E donor rats. However, transfer of two-cell embryos from Diabetic DP- into Non-Diabetic DR-BB/E mothers did not prevent the development of an ICM cellular deficit or a TE cell accretion - implying earlier damage to the germ cells. Greatly improved metabolic control was achieved in Diabetic DP-BB/E rats before and over the period of conception using sustained release insulin implants. This resulted in a reduction in the number of unfertilised oocytes, an increase in the percentage of expanded blastocysts but no change in ICM cellular deficit. A sensitive and accurate quantitative RT-PCR method was developed and used to determine the ratio of bcl-2 (a cell death agonist gene) to bax (a cell death antagonist gene) expression in single blastocysts from Diabetic DP- and Non-Diabetic DR-BB/E rats. Although the bcl-2 to bax ratio was not significantly increased in blastocytes from diabetic rats, these data demonstrate for the first time that bax and bcl-2 mRNA is present in the pre-implantation embryo.
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Jason Tsz Chun. "Prevention of type 1 diabetes by carbamazepine in non-obese diabetic mice." Thesis, University of British Columbia, 2017. http://hdl.handle.net/2429/62704.

Full text
Abstract:
Pancreatic β cells are selectively destroyed by the host immune system in type 1 diabetes, which results in the inability to regulate glucose homeostasis due to loss of insulin production capacity. Drugs that preserve β cell mass and function therefore have the potential to prevent or slow the progression of this disease. It was recently reported by our group that the use-dependent sodium channel blocker, carbamazepine, protects pancreatic β cells from inflammatory cytokines in vitro. Subsequent experiments found carbamazepine increased insulin gene expression, which corroborated with an increase in insulin content in islets from mice lacking the Nav1.7 voltage gated sodium channel, which was shown to be a target of carbamazepine in β cells. While these in vitro results were promising, it was unclear whether carbamazepine would protect β cells in vivo against a complete immune system. Therefore, we tested the effects of oral treatment in female non-obese diabetic (NOD) mice, achieving serum carbamazepine levels of 14.98 ± 3.19 μM. Remarkably, diabetes incidence over 25 weeks was ~50% lower in carbamazepine treated animals. Partial protection from diabetes in carbamazepine-fed NOD mice was also associated with improved glucose tolerance at 6 weeks of age, prior to the onset of diabetes in our colony. Insulitis was improved in carbamazepine treated NOD mice at 6 weeks of age, but we did not observe differences in CD4⁺ and CD8⁺ T cell composition in the pancreatic lymph node, as well as circulating markers of inflammation. Taken together, our results demonstrate that carbamazepine reduces the development of type 1 diabetes in NOD mice.
Medicine, Faculty of
Graduate
APA, Harvard, Vancouver, ISO, and other styles
7

van, Netten Jaap J., Peter A. Lazzarini, David G. Armstrong, Sicco A. Bus, Robert Fitridge, Keith Harding, Ewan Kinnear, et al. "Diabetic Foot Australia guideline on footwear for people with diabetes." BIOMED CENTRAL LTD, 2018. http://hdl.handle.net/10150/626601.

Full text
Abstract:
Background: The aim of this paper was to create an updated Australian guideline on footwear for people with diabetes. Methods: We reviewed new footwear publications, (international guidelines, and consensus expert opinion alongside the 2013 Australian footwear guideline to formulate updated recommendations. Result: We recommend health professionals managing people with diabetes should: (1) Advise people with diabetes to wear footwear that fits, protects and accommodates the shape of their feet. (2) Advise people with diabetes to always wear socks within their footwear, in order to reduce shear and friction. (3) Educate people with diabetes, their relatives and caregivers on the importance of wearing appropriate footwear to prevent foot ulceration. (4) Instruct people with diabetes at intermediate-or high-risk of foot ulceration to obtain footwear from an appropriately trained professional to ensure it fits, protects and accommodates the shape of their feet. (5) Motivate people with diabetes at intermediate-or high-risk of foot ulceration to wear their footwear at all times, both indoors and outdoors. (6) Motivate people with diabetes at intermediate-or high-risk of foot ulceration (or their relatives and caregivers) to check their footwear, each time before wearing, to ensure that there are no foreign objects in, or penetrating, the footwear; and check their feet, each time their footwear is removed, to ensure there are no signs of abnormal pressure, trauma or ulceration. (7) For people with a foot deformity or pre-ulcerative lesion, consider prescribing medical grade footwear, which may include custom-made in-shoe orthoses or insoles. (8) For people with a healed plantar foot ulcer, prescribe medical grade footwear with custom-made in-shoe orthoses or insoles with a demonstrated plantar pressure relieving effect at high-risk areas. (9) Review prescribed footwear every three months to ensure it still fits adequately, protects, and supports the foot. (10) For people with a plantar diabetic foot ulcer, footwear is not specifically recommended for treatment; prescribe appropriate offloading devices to heal these ulcers. Conclusions: This guideline contains 10 key recommendations to guide health professionals in selecting the most appropriate footwear to meet the specific foot risk needs of an individual with diabetes.
APA, Harvard, Vancouver, ISO, and other styles
8

Beshay, Evette A. "Prevention of type 1 diabetes with phosphodiesterase inhibitors." Thesis, McGill University, 2001. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=38152.

Full text
Abstract:
The phosphodiesterase (PDE) inhibitors Pentoxifylline (PTX), a general inhibitor, and Rolipram (ROL), a type 4 inhibitor, have been shown to have anti-inflammatory effects. They elevate intracellular CAMP levels and suppress the production of inflammatory cytokines such as tumor necrosis factor (TNF)alpha, interferon (IFN)gamma, and interleukin-12 (IL-12). These drugs have also been reported to modulate the immune response in favor of Th2 responses and to be therapeutically effective in various models of autoimmune and/or inflammatory disorders. Their effects on nitric oxide (NO) production are not well studied. Inflammatory cytokines and NO are important mediators implicated in islet beta-cell destruction.
In the first part of the study, we examined the effect of PTX and ROL in preventing insulitis and diabetes in non-obese diabetes-prone (NOD) mice as a spontaneous model of insulin-dependent diabetes (IDDM). We found that a 4 week treatment with either PTX or ROL had a strong protective effect, that was still apparent 11 weeks after withdrawing the drugs. Both drugs were equally effective at optimal doses in preventing mstiulitis and diabetes in NOD mice.
In the second part of the study, we examined the effects of PDE inhibitors on NO production by peritoneal macrophages and RAW 246.7 cells. We also correlated these effects with elevated cAMP levels. We found that both PTX and ROL suppress NO production by IFNgamma and lipopolysaccharide (LPS)-activated macrophages. The inhibitory effects correlated with elevated CAMP levels and were mimicked by other agents which elevate CAMP levels such as dibutyryl cAMP, 8-bromo cAMP, and Forskolin. This suppression was found to be at the transcriptional level. In vivo, ROL treatment prevented macrophage activation by staphylococcal enterotoxin B (SEB) and suppressed NO production by these macrophages in ex vivo culture.
In the third part of the study, we examined the effects of PDE inhibitors on NO production by insulin-producing NIT-1 insulinoma cells and normal islet cells. It has been reported that islet beta-cells express PDE3 and PDE4. We found that inhibitors of PDE4 (ROL), PDE3 (Cilostamide; CIL), or a general inhibitor (PTX), suppressed NO production by islet cells. A combination of ROL and CIL appeared to have more than an additive effect, suggesting synergism. Like in macrophages, the suppression was at the transcriptional level and mimicked by other agents which elevate cAMP levels. In vivo, ROL treatment suppress iNOS expression in the islets of NOD mice with cyclophosphamide-accelerated disease, as determined by immunohistochemistry.
These studies establish for the first time that PDE inhibitors have a therapeutic potential in IDDM and other NO-and/or cytokine-mediated inflammatory disorders.
APA, Harvard, Vancouver, ISO, and other styles
9

Arun, Chankramath S. "Retinopathy screening : prevention of blindness due to diabetes." Thesis, University of Newcastle Upon Tyne, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.427289.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cardona-Morrell, Magnolia. "Evaluation of a Community-wide Diabetes Prevention Program." Phd thesis, University of Sydney, 2011. http://hdl.handle.net/2123/8349.

Full text
Abstract:
This thesis is an evaluation of the effectiveness of a community-wide diabetes prevention program conducted in three Divisions of General Practice in Sydney, Australia. The aims were to assess whether translation of diabetes prevention programs was feasible in real-life settings and whether results achieved were comparable with those of randomised trials on which this intervention was based. Its primary goals were to assess whether the lifestyle intervention could increase participation in moderate-to-vigorous physical activity to 210 minutes per week, reduce total fat and saturated fat consumption to 30% and 10% of total daily energy intake, increase fibre consumption to 15 g/1,000 kcal/day, and lead to 5% weight loss over one year. The background section covers the physiopathology of type 2 diabetes, its risk factors, and the available population screening tools to identify people at risk. The growing morbidity and mortality burden, the economic implications of this public health problem, and the importance and feasibility of preventing or delaying the onset by intervening in the precursor stages are then summarised. Evidence for preventability is examined through a literature review of lifestyle interventions in research settings comprising highly structured and closely monitored physical activity and dietary programs under controlled conditions. Examples of the effectiveness of translation of randomised controlled trials (RCTs) into less stringent programs in community settings such as workplaces, churches, indigenous communities and whole-of-country initiatives are presented. A systematic review and meta-analysis of effectiveness of the lifestyle approaches in routine clinical practice supplements the evidence for application of prevention principles in real-life settings. The main chapters of the thesis centre on process and impact evaluation of the semi-structured Sydney-based intervention, which recruited 1,250 participants from the mainstream Australian 29 public using general practitioner services in the study area, who were followed for 12 months. The intervention’s goals aligned with those of the Finnish Diabetes Prevention Program but with less stringent entry criteria and less intensive intervention components delivered by purpose-trained lifestyle officers. The Program included an initial individual assessment and coaching session, three subsequent group sessions in the following three months, then three follow-up coaching calls at three, six and nine months. A final assessment at one year, using the same objective and self-reported measures as in the initial assessment, captured changes in body weight, physical activity and dietary habits. The process evaluation showed that it is feasible and effective to use targeted screening to identify and recruit high-risk individuals into a free-of-charge program in the general practice setting, however a quarter of participants were lost to follow-up by one year. While minor variations in aspects of the Program were required to meet local need, Program fidelity in delivering components, and self-reported adherence to diet and physical activity was high. Using a before-after study design, the impact evaluation measured 1-year changes in key Program parameters in relation to baseline. These comprised: measured weight, waist circumference, BMI, and glycaemia measurements; and self-reported dietary intake and structured physical activity, using a 3-day food record and the Physical Activity Scale for the Elderly (PASE) questionnaire, respectively. The main findings at 12 months for the 586 completers as at December 2010 were: a mean weight loss of 2.1 kg; waist circumference reduction of 2.5 cm; no significant change in glycaemia; 3% reduction of fat and saturated fat intake; 16% increase in fibre intake; and mean increase in moderate-to-vigorous physical activity of 13.7 minutes/week. All these changes were smaller than those achieved by the RCTs in research settings, most likely due to the lower intensity and monitoring of the Sydney intervention. Weight loss and waist circumference reductions were similar for participants in 30 group session and those who received telephone-only coaching. Diabetes incidence was 1% at the end of the first year. An economic appraisal of the Program implementation completes the evaluation. A cost of A$400 per kg lost among people achieving the weight goal was estimated on Program completion, but the cost was double for the overall group that included non weight losers. The cost of achieving the physical activity goal and the dietary goals was not feasible or sustainable with resources available in routine clinical settings. The costs per outcome were similar for participants not attending group sessions, who received only telephone coaching. Hence it is worth exploring this less labour-intensive modality if a general practice based Program were to be delivered as routine preventive care. In sum, the evaluation of this community-wide diabetes prevention program showed that translation of diabetes prevention programs into routine practice, while feasible at less intensive levels than in RCTs, has a somewhat lower effect on diabetes risk reduction and it can still be a financial burden in clinical settings. However, given the potential for population-wide benefit, the effectiveness of alternative delivery modes, number and duration of program components and more targeted patient sub-groups should be investigated.
The Sydney Diabetes Prevention Program was funded by New South Wales Health as part of the Australian Better Health Initiative. Financial contribution and other in-kind support were provided by the Sydney South West Area Health Service and the Australian Diabetes Council -NSW.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Diabetes – Prevention"

1

Schwarz, Peter, and Prasuna Reddy, eds. Prevention of Diabetes. Oxford, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118661321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Broadhurst, C. Leigh. Diabetes: Prevention and cure. New York: Kensington, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Beales, Philip Edward. Diabetes prevention in the non-obese diabetic mouse. London: University of East London, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

LeRoith, Derek, ed. Prevention of Type 2 Diabetes. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-3314-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ganz, Manfred, ed. Prevention of Type 2 Diabetes. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470857358.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Manfred, Ganz, ed. Prevention of type 2 diabetes. Chichester, England: Wiley, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wellness, Alberta Alberta Health and. Alberta Diabetes Strategy: 2003-2013. [Edmonton, Alta: Alberta Health & Wellness], 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

van, Schilfgaarde R., and International Symposium on Complications of Diabetes, Current Status of Prevention and Treatment (1986 : Hague, Netherlands), eds. Complications of diabetes: Prevention and treatment. Orlando: Grune & Stratton, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

National Diabetes Education Program (U.S.), National Institutes of Health (U.S.), and Centers for Disease Control and Prevention (U.S.), eds. Prevent type 2 diabetes =: Prevengamos la diabetes tipo 2. [Washington, D.C.]: National Diabetes Education Program, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

A, Hitman Graham, ed. Type 2 diabetes: Prediction and prevention. Chichester: J. Wiley, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Diabetes – Prevention"

1

Thomas-Geevarghese, Asha, and Kevan C. Herold. "Diabetes Prevention." In Principles of Diabetes Mellitus, 739–58. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-1-4757-6260-0_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hivert, Marie-France, and William C. Knowler. "Diabetes Prevention." In The Genetics of Type 2 Diabetes and Related Traits, 521–37. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-01574-3_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sosenko, Jay M. "Diabetes." In Prevention in Clinical Practice, 165–77. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5356-0_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Marrero, David G. "Diabetes Prevention Program." In Encyclopedia of Behavioral Medicine, 644–45. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_1199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Upchurch Sweeney, C. Renn, J. Rick Turner, J. Rick Turner, Chad Barrett, Ana Victoria Soto, William Whang, Carolyn Korbel, et al. "Diabetes Prevention Program." In Encyclopedia of Behavioral Medicine, 579–81. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_1199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hu, Gang. "Diabetes Mellitus, Prevention." In Encyclopedia of Exercise Medicine in Health and Disease, 243–45. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lindström, Jaana. "What Have We Learned from the Number of Clinical Trials?" In Prevention of Diabetes, 1–14. Oxford, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118661321.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kronsbein, Peter. "Training of Prevention Managers." In Prevention of Diabetes, 144–58. Oxford, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118661321.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yates, Thomas, Melanie Davies, and Kamlesh Khunti. "Prevention of Type 2 Diabetes: the Role of Physical Activity." In Prevention of Diabetes, 159–76. Oxford, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118661321.ch11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tolks, Daniel, and Martin R. Fischer. "Overview: Potentials of New Media for the Training of Health Educators in the Field of Diabetes Prevention." In Prevention of Diabetes, 177–94. Oxford, UK: John Wiley & Sons, Ltd, 2013. http://dx.doi.org/10.1002/9781118661321.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Diabetes – Prevention"

1

Oliveira, Filipe A. C., Felipe M. Dias, Marcelo A. F. Toledo, Diego A. C. Cardenas, Douglas A. Almeida, Estela Ribeiro, Jose E. Krieger, and Marco A. Gutierrez. "Machine Learning-Based Diabetes Detection Using Photoplethysmography Signal Features." In Simpósio Brasileiro de Computação Aplicada à Saúde. Sociedade Brasileira de Computação - SBC, 2024. http://dx.doi.org/10.5753/sbcas.2024.1889.

Full text
Abstract:
Diabetes is a chronic condition which prevention and control is done mostly by minimally invasive devices. In this work, we propose a noninvasive method based on photoplethysmography (PPG) for cost-effective and discomfort-free diabetes detection and prevention. We used PPG signal features and patient metadata from a public dataset for classifying subjects as Diabetic or non-Diabetic. The Logistic Regression and eXtreme Gradient Boosting algorithms were evaluated using a five-fold cross validation approach and achieved a mean AUC of 0.79 ± 0.15 and 0.73 ± 0.17, respectively. Our results align with existing literature, supporting the use of machine learning techniques for developing non-invasive diabetes detection and prevention devices.
APA, Harvard, Vancouver, ISO, and other styles
2

Mayurnikova, L., A. Koksharov, N. Gornikov, T. Krapiva, and S. Novosyolov. "Phyto-beverages in diabetes prevention." In I INTERNATIONAL CONFERENCE ASE-I - 2021: APPLIED SCIENCE AND ENGINEERING: ASE-I - 2021. AIP Publishing, 2021. http://dx.doi.org/10.1063/5.0075967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Daban, Alaa Hasan. "The prevalence of statin prescription for primary prevention of Arteriosclerotic Cardiovascular Diseases among patients with Type 2 Diabetes in Qatar." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0098.

Full text
Abstract:
Background: Qatar has one of the highest prevalence rates for diabetes in the world. Arteriosclerotic cardiovascular diseases (ASCVDs) are responsible for nearly 50% of deaths among patients with diabetes in Qatar. Treating with statins is a simple and effective approach for preventing ASCVD among patients with diabetes. Local and international guidelines recommend the use of statins for primary prevention of ASCVD in patients with diabetes, especially for those 40-75 years of age. Yet statins are still under-prescribed to diabetic individuals for primary prevention of ASCVD worldwide, especially in primary care settings which is where most of the medical management of diabetes occurs. Little is known about the prevalence of statin prescription for primary prevention of ASCVD among diabetics in primary care settings in Qatar. Objectives: To measure the proportion of T2dm patients receiving statins for primary prevention of ASCVD in primary care settings and to investigate patients’ characteristics associated with statin prescription. Results: Of 23,934 patients with complete data, 57% were males and 31.9% were Qatari nationals. Average age for participants was 54.8 ± 8.25 years. 66 % of the patients received statins at least once during the year 2019. The statin prescription rate for Non-Qatari males was 70.1% and was significantly higher than non-Qatari females, Qatari females, or Qatari males (62.2%, 62.9% and 63.9% respectively P value <0.000) In a multivariable model analysis and after controlling for other covariates in the model, statin prescription was positively associated with being male (adjusted odds ratio (aOR): 1.2, [95% CI: 1.12-1.28]), history of smoking, i.e. former smoker (aOR 1.16 [95% CI: 1.03-1.29]), current smoker (aOR 1.11 [95% CI: 1.01-1.22 ]), associated diagnosis of hypertension (aOR 1.51 [95% CI: 1.41-1.61]), being prescribed other non-statin lipids lowering medications (aOR 1.44 [95% CI: 1.27-1.63]), increased age (aOR 1.03/year [95% CI: 1.026-1.034]), increasing daily pill burden (aOR 1.23/pill [95% CI: 1.21-1.25]), increasing number of daily medication injections (aOR 1.29/injection [95% CI: 1.23-1.35]), and frequent visits to GP clinic (aOR 1.22/visit [95% CI: 1.19-1.24]). Statin prescription was negatively associated with having a history of diabetic neuropathy (aOR 0.87 [95% CI: 0.75-1.0]), increasing BMI (aOR 0.996/unit [95% CI: 0.9892-1.00]), being Qatari (aOR 0.87 [95% CI: 0.81-0.93]) or being prescribed an anti-platelet (aOR 0.96/unit [95% CI: 0.89-1.03]). Significant negative effect modification between hypertension and either male gender or Qatari nationality was found, further lowering the odds for Qatari males. Conclusion: Prevalence of statin prescription for primary prevention of ASCVD among patients with T2dm was suboptimal in primary care settings in Qatar and need to be improved. Factors associated with a lower prevalence of statin prescription namely female gender and Qatari nationality needs to be addressed. Further studies are needed to explore causes of the low prescription rates of statins in Qatar.
APA, Harvard, Vancouver, ISO, and other styles
4

Timofeev, M. V., and M. M. Nagornova. "SPORT AS A PREVENTION FOR DIABETES MELLITUS." In Х Всероссийская научно-практическая конференция. Nizhnevartovsk State University, 2021. http://dx.doi.org/10.36906/fks-2020/60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Handayani, Oktia Woro, Siti Fathonah, and Arif Kurnia. "Rice Bran for Diabetes Mellitus Prevention and Snackification." In Proceedings of the 5th International Seminar of Public Health and Education, ISPHE 2020, 22 July 2020, Universitas Negeri Semarang, Semarang, Indonesia. EAI, 2020. http://dx.doi.org/10.4108/eai.22-7-2020.2300303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Palawat, Nattacha, Supaporn Kiattisin, and Theeraya Mayakul. "A Smart Prevention Management in Gestational Diabetes Mellitus." In 2022 IEEE Global Humanitarian Technology Conference (GHTC). IEEE, 2022. http://dx.doi.org/10.1109/ghtc55712.2022.9911041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dao, Dung, Jun Yi Claire Teo, Wenru Wang, and Hoang D. Nguyen. "LLM-Powered Multimodal AI Conversations for Diabetes Prevention." In ICMR '24: International Conference on Multimedia Retrieval. New York, NY, USA: ACM, 2024. http://dx.doi.org/10.1145/3643479.3662049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhu, Liang, and Robert Flower. "Role of Vasomotion in Control of Retina Edema in Diabetic Retinopathy: Quantification of Fluid Transport Through Retinal Capillaries." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-189507.

Full text
Abstract:
Diabetic retinopathy refers to diabetes-related complications in the retina, It is a progressive disease and its symptoms in the eyes can vary from non-vision threatening to vision loss, and it can lead to permanent damage to the neuronal retinal tissue. The irreversible nature of the damage suggests that prevention of diabetes by eliminating risk factors and early screening are the cornerstone of relevant treatment to stop or limit visual damage in those patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Loku, Lindita, Bekim Fetaji, and Majlinda Fetaji. "Prevention Of Diabetes By Devising A Prediction Analytics Model." In 2020 International Congress on Human-Computer Interaction, Optimization and Robotic Applications (HORA). IEEE, 2020. http://dx.doi.org/10.1109/hora49412.2020.9152894.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cao, Ni, Sisi Zeng, Feixia Shen, Chuandi Pan, Chengshui Chen, Thanh Nguyen, and Jake Chen. "Predictive and preventive models for diabetes prevention using clinical information in electronic health record." In 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2015. http://dx.doi.org/10.1109/bibm.2015.7359799.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Diabetes – Prevention"

1

Caffo, Olenka, W. Joshua Earl, Lauren Luscuskie, and Ariana Trautmann. Use of Video Education to Gain Attendance at Diabetes Prevention Courses. Florida State University College of Medicine, April 2019. http://dx.doi.org/10.17125/1561992648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Siminerio, Linda M., Barbara E. Barnes, and Megan G. Marks. Diabetes Prevention and Treatment Programs for Western PA FY04 and FY05. Fort Belvoir, VA: Defense Technical Information Center, May 2009. http://dx.doi.org/10.21236/ada509746.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Trucco, Massimo. New Advanced Technology to Improve Prediction and Prevention of Type I Diabetes. Fort Belvoir, VA: Defense Technical Information Center, November 2001. http://dx.doi.org/10.21236/ada400015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Trucco, Massimo. New Advanced Technology to Improve Prediction & Prevention of Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, November 2004. http://dx.doi.org/10.21236/ada430563.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Trucco, Massimo. New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, November 2002. http://dx.doi.org/10.21236/ada412787.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vigersky, Robert A. New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, November 2005. http://dx.doi.org/10.21236/ada469956.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Trucco, Massimo. New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, November 2006. http://dx.doi.org/10.21236/ada469957.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mejia-Lancheros, Cilia, Zayd Hafiz Hafiz, Michelle Hwang, Diana Sherifali, Angela J. Carte, Gurpreet Malhotra, Ansjyot Kappor, and Ian Zenlea. Health and wellness coaching for Type 2 diabetes prevention: A Systematic Scoping Review Protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2023. http://dx.doi.org/10.37766/inplasy2023.11.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vakhlova, Irina, Irina Zaikova, Alexey Kiyaev, and Yulia Ibragimova. Electronic educational resource (EOR) "Module. Diabetes mellitus in children". SIB-Expertise, January 2024. http://dx.doi.org/10.12731/er0781.29012024.

Full text
Abstract:
Diabetes mellitus occupies a leading place in the pathology of the endocrine system in children and adolescents and remains one of the most urgent health problems in most countries. In the last decade, the annual incidence of type 1 diabetes in children has shown a significant increase both in Russia and around the world. According to the International Diabetes Federation (IDF), it is increasing by 3% per year. In addition, in all European countries there is a "phenomenon of rejuvenation of diabetes" - an increase in the proportion of children who first fell ill with type 1 diabetes at a younger age: 25-30% up to 4 years of age; up to 80% - from 6 months to 9 years. The annual incidence of type 1 diabetes in children (0-14 years old) in the Sverdlovsk region over the past decade (2006-2017) has almost doubled: from 12.2 cases per 100 thousand children in 2006 to 23 ,7 in 2017 and occupies one of the leading places in the Russian Federation in this indicator. More than 200 children with type 1 diabetes are diagnosed per year, of which about 75% of children who become ill for the first time are under the age of 9 years. Type 1 diabetes is characterized by complete insulin dependence, severe course, early formation of specific complications that lead to a decrease in the quality and life expectancy. Unfortunately, in more than 70% of cases, DM is diagnosed at the stage of ketoacidosis, which requires urgent measures. The main reason for the late diagnosis of this disease is the lack of "diabetic alertness" among pediatricians and AFP physicians. The foregoing obliges a wide range of doctors, including pediatricians, to know the clinical and laboratory criteria for diagnosis, modern methods of monitoring and managing diabetes, possible complications and outcomes of the disease, and be able to provide emergency care. Timely diagnosis, self-monitoring, regular monitoring, prevention of complications is an opportunity to improve the quality of life of patients with diabetes.
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Bin, Fei Wen, Hongru Chen, and Ri-Li Ge. A meta analysis of the prevalence rate of diabetic retinopathy. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0112.

Full text
Abstract:
Review question / Objective: P: diabetic retinopathy; I:—; C:—; O: prevalecne rate; S:cross-sectional study. Objective:To analyze the epidemiological characteristics of diabetic retinopathy and to provide scientific basis for its prevention and control． Condition being studied: Diabetic retinopathy is one of the common microvascular complications in patients with diabetes mellitus, which ultimately seriously affects the vision of patients. It is the leading cause of blindness among young and middle-aged workers worldwide. It is one of the main causes of binocular blindness in elderly patients in western countries.Because of the high incidence, wide range, complex pathogenesis, serious consequences and poor treatment effect of DM and its DR,many countries have actively carried out epidemiological research on the population of DM patients in order to understand the incidence, distribution and related risk factors of DR, and to provide scientific basis for the formulation of targeted public prevention and control measures.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Diabetes – Prevention' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography